Crossmark

Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer

Crossref DOI link: https://doi.org/10.1186/s12917-018-1411-6

Published Online: 2018-03-12

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zambrano-Estrada, Xóchitl

Landaverde-Quiroz, Brianda

Dueñas-Bocanegra, Andrés A.

De Paz-Campos, Marco A.

Hernández-Alberto, Gerardo

Solorio-Perusquia, Benjamín

Trejo-Mandujano, Manuel

Pérez-Guerrero, Laura

Delgado-González, Evangelina

Anguiano, Brenda

Aceves, Carmen https://orcid.org/0000-0001-9418-8304
Funding

Funding for this research was provided by:

PAPIIT-UNAM (200813, 201516, 209717)

CONACYT (235961, 356685)
License Information

Text and Data Mining valid from 2018-03-12
More Information

Article History

Received: 8 November 2017

Accepted: 5 March 2018

First Online: 12 March 2018

Consent for publication

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.